Boyang Wang, founder of venture fund Immortal Dragons, invests in moonshot projects to extend life and challenge medicine’s core philosophy
The science of aging and lifespan—often called geroscience—is surrounded by hype and skepticism. Mainstream coverage tends to focus on non-rigorous claims about supplements that extend lifespan in mice or on ideas so extreme they feel ethically and technically out of reach. Just in the past year, the idea of organ swapping and head transplants went from a fiction plotline to a topic being discussed by world leaders caught on a hot mic.
Today’s guest believes it is. Boyang Wang is the founder of Singapore-based longevity investment firm Immortal Dragons, a fund dedicated to supporting companies working to extend lifespan and healthspan. These investments range from organ printing to preventative gene therapies and vaccines for high-risk patients with complex, resource-draining diseases. Some of these ideas no longer live at the edge of imagination; instead, they raise deeper questions about how we define medicine, prevention, and aging itself.
Trained as a computer scientist, Wang found success as an engineer and entrepreneur in the tech world. After building a stable business, he decided to focus his time and resources on what mattered most to him: human longevity. Immortal Dragons is now managing its first fund, a $40 million vehicle that has backed roughly a dozen underfunded longevity companies—placing bold bets on what the future of medicine might become.
Listen (or read the full transcript) at this link: